Detailed financial statements for Anbio Biotechnology Class A Ordinary Shares (NNNN): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B).
Analysis Summary
Trailing-twelve-month margins: gross margin 86.1%, operating margin 65.2%, net margin 72.1%.
At the current price of $5.58, NNNN trades at a P/E of 28.85 and an ROE of 27.49%. Market capitalisation stands at $245M.
Balance sheet quality for NNNN: current ratio of 344.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of -$6.7M represents -105% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.4M | $23.5M | $6.7M | $8.2M | $8.6M |
| Cost of Revenue | $1.9M | $11.0M | $3.4M | $2.3M | $1.1M |
| Gross Profit | $2.5M | $12.6M | $3.4M | $5.9M | $7.5M |
| Research & Development | 0 | $200000 | $134700 | $454227 | $201305 |
| Selling, General & Admin | $86095 | $2.2M | $1.3M | $3.4M | $1.6M |
| Operating Expenses | $86095 | $2.4M | $1.4M | $3.9M | $1.8M |
| Operating Income | $2.5M | $10.2M | $2.0M | $2.0M | $5.8M |
| EBITDA | $2.5M | $10.0M | $2.3M | $2.0M | $5.8M |
| Interest Expense | 0 | $7999 | 0 | 0 | 0 |
| Pre-tax Income | $2.5M | $10.0M | $2.3M | $2.4M | $6.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Net Income | $2.5M | $10.0M | $2.3M | $2.4M | $6.4M |
| EPS | $0.03 | $0.07 | $0.02 | $0.06 | $0.16 |
| EPS (Diluted) | $0.03 | $0.07 | $0.01 | $0.06 | $0.16 |
| Shares Outstanding (Diluted) | $100.0M | $143.9M | $187.8M | $42.3M | $43.9M |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $7.1M | $9.7M | $11.8M | $7.8M |
| Short-term Investments | 0 | $1.6M | 0 | 0 | $4.1M |
| Receivables | $717500 | $3581 | $1.9M | $1.1M | $3.7M |
| Inventory | 0 | $353872 | 0 | 0 | 0 |
| Total Current Assets | $4.9M | $13.9M | $15.7M | $18.5M | $30.2M |
| Property, Plant & Equipment | 0 | $12059 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.9M | $14.0M | $15.8M | $18.9M | $30.2M |
| Accounts Payable | $1.9M | $1.4M | $827151 | $1.6M | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.4M | $1.4M | $993060 | $1.7M | $87836 |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.4M | $1.4M | $993060 | $1.7M | $87836 |
| Retained Earnings | $2.5M | $12.5M | $14.8M | $17.2M | $23.6M |
| Total Equity | $2.5M | $12.5M | $14.8M | $17.2M | $30.2M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$4.2M | -$8.7M | -$9.7M | -$11.8M | -$11.9M |
| Working Capital | $2.5M | $12.5M | $14.8M | $16.8M | $30.2M |
Cash Flow (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Income | $2.5M | $10.0M | $2.3M | $2.4M | $6.4M |
| Depreciation & Amortization | 0 | $6252 | $12059 | 0 | 0 |
| Stock-based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | $1.6M | -$5.5M | -$1.2M | $44646 | -$13.2M |
| Operating Cash Flow | $4.2M | $4.4M | $898367 | $2.1M | -$6.7M |
| Capital Expenditure | 0 | -$3 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | $4.2M | $4.4M | $898367 | $2.1M | -$6.7M |
Growth & Margins (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth (YoY) | +431.7% | -71.5% | +21.9% | +5.6% | |
| Net Income Growth (YoY) | +294.8% | -77.5% | +5.3% | +169.9% | |
| EPS Growth (YoY) | +174.0% | -77.4% | +256.7% | +185.7% | |
| Shares Change (YoY) | +43.9% | +30.5% | -77.5% | +3.8% | |
| FCF Growth (YoY) | +6.4% | -79.8% | +131.6% | -423.9% | |
| Gross Margin | 57.4% | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating Margin | 55.5% | 43.3% | 29.2% | 24.4% | 66.7% |
| EBITDA Margin | 57.3% | 42.6% | 33.8% | 24.4% | 66.7% |
| Net Margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |
| FCF Margin | 94.4% | 18.9% | 13.4% | 25.4% | -77.9% |
| Effective Tax Rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Per-Share Data (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| FCF Per Share | $0.04 | $0.03 | $0.00 | $0.05 | $-0.15 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $100.0M | $143.9M | $143.9M | $42.3M | $43.9M |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Return on Equity | 27.49% |
| Return on Invested Capital | 25.46% |
| Return on Assets | 28.07% |
| Gross Margin | 86.10% |
| Operating Margin | 65.20% |
| Net Margin | 72.09% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 344.31 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 9018.70 |
Key Ratios (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| P/E | 227.17 | 82.90 | 367.52 | 103.04 | 187.94 |
| P/B | 227.54 | 66.17 | 56.03 | 14.19 | 43.77 |
| P/S | 130.29 | 35.26 | 123.70 | 29.81 | 152.63 |
| Gross Margin | 57.4% | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating Margin | 55.5% | 43.3% | 29.2% | 24.4% | 66.7% |
| Net Margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |
Related companies: ANGO · AVNS · CLPT · CMPS · CYH · GOSS · KALV
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NNNN: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks